Cytomorphological and immunocytochemical study of non-Hodgkin's lymphoma in pleural effusion and ascitic fluid
Cytomorphological and immunocytochemical study of non-Hodgkin's lymphoma in pleural effusion and ascitic fluid
复制标题
DOI：
10.1111/j.1365-2303.2007.00448.x
复制
发表时间：
2007-06-01
期刊：
影响因子：
1.3
通讯作者：
Kapila, K.
中科院分区：
文献类型：
--
作者：
Das, D. K.;Al-Juwaiser, A.;Kapila, K.
前言：非霍奇金淋巴瘤(NHL)常合并胸腔积液和腹水。方法：对31例恶性胸腔积液标本进行May-Grunwald-Giemsa和Papanicolaou染色。其中，根据WHO淋巴瘤分类系统，对22例患者的12例胸腔积液和10例腹水标本进行了详细的细胞学评估。结果：根据细胞学特征，将22例恶性胸腔积液标本分为淋巴浆细胞样淋巴瘤(1例)、滤泡中心细胞(FCC)1级(中心细胞性)淋巴瘤(3例)、FCC 2级(中心细胞性)淋巴瘤(3例)、FCC 3级(中心母细胞性)淋巴瘤(4例)、大细胞免疫母细胞性淋巴瘤(4例)、淋巴母细胞性淋巴瘤(2例)、间变性大细胞淋巴瘤(3例)和其他类型淋巴瘤(2例)。免疫细胞化学结果显示，T细胞型(CD3阳性)5例，B细胞型(CD20阳性)6例。结论：胸腹水细胞学检查结合免疫细胞化学结果，可作为世界卫生组织淋巴瘤分类的依据。
Introduction: Non-Hodgkin's lymphoma (NHL) is often complicated by pleural effusion and ascites. The present study is an attempt to categorize the lymphomatous effusions according to the WHO classification, using archival material.Methods: May-Grunwald-Giemsa and Papanicolaou-stained smears of 31 lymphomatous effusion specimens were reviewed. Of these, detailed cytological assessment was done on 12 pleural effusions and ten ascitic fluid specimens from 22 patients using the WHO lymphoma classification system. Immunocytochemical studies were performed in 21 specimens.Results: Based on cytomorphological features, the 22 lymphomatous effusion specimens were categorized into lymphoplasmacytoid lymphoma (1), follicle centre cell (FCC) grade-1 (centrocytic) lymphoma (3), FCC grade-2 (centrocytic-centroblastic) lymphoma (3), FCC grade-3 (centroblastic) lymphoma (4), large cell immunoblastic lymphoma (4), lymphoblastic lymphoma (2), anaplastic large cell lymphoma (3) and miscellaneous types (2). Immunocytochemically, the lymphoma cells were T-cell (positive for CD3) and B-cell type (CD20 positive) in five and six cases respectively.Conclusion: Cytological examination of pleural effusion and ascitic fluid samples, supported by immunocytochemical studies, may be useful for the classification of lymphomas under the WHO system.